Scarica l'app Stockscreener
0.58
0.99%
-0.0058
Dopo l'orario di chiusura:
.55
-0.03
-5.17%
BiomX Inc Borsa (PHGE) Ultime notizie
What is HC Wainwright’s Estimate for BiomX FY2025 Earnings? - Defense World
What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World
HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy By Investing.com - Investing.com South Africa
Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 - Investing.com India
Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com Australia
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire
BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India
Critical Audit Alert: BiomX Receives Going Concern OpinionWhat This Means - Stock Titan
BiomX Announces Positive Phase 2 Trial Results - TipRanks
BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia
BiomX reports progress in diabetic ulcer treatment - Investing.com India
BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener
BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire
Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan
Phage Therapy Market Know the Scope and Trends - openPR
BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World
BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus
BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire
Earnings Scheduled For March 25, 2025 - Benzinga
BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire
BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq
BiomX Sets Major Double Update: Q4 Earnings Plus Crucial Phase 2 Osteomyelitis Data - Stock Titan
BiomX’s $12 Million Financing - Global Legal Chronicle
BiomX Inc. secures $12 million from recent offerings - Investing.com India
Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today
BiomX Announces $12M Funding for BX004 Study - TipRanks
BiomX announces series of financings for aggregate gross proceeds of $12M - MSN
BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire
Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan
BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World
Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve
BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World
Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World
Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.
Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire
Barclays PLC Sells 225,000 Shares of BiomX Inc. (NYSEMKT:PHGE) - Defense World
HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE) - Defense World
BiomX (NYSEMKT:PHGE) Stock Price Down 1.3% – Here’s Why - Defense World
BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):